Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 30. Analyst Laura Chico from Wedbush reiterated a Buy rating on the stock and has a $26.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Laura Chico’s rating is based on the promising commercial dynamics and opportunities within Travere Therapeutics’ pipeline, particularly surrounding Filspari. The company is positioned well in the competitive landscape of IgA nephropathy (IgAN) treatments, with Filspari expected to cater to a unique niche as per updated treatment guidelines. Furthermore, there is optimism regarding the potential alignment between the FDA and Travere Therapeutics for a Filspari indication in focal segmental glomerulosclerosis (FSGS), which could significantly boost revenues.
Additionally, Chico projects strong financial prospects for Travere Therapeutics, estimating a substantial increase in revenue driven by Filspari’s success. The anticipated adoption of Filspari, in conjunction with its competitive advantage over similar therapies like atrasentan, underscores its significance in multi-drug treatment regimens for IgAN. The potential for additional market penetration, combined with the company’s sufficient cash reserves extending into 2028, supports a positive outlook and the Buy rating.
According to TipRanks, Chico is a 4-star analyst with an average return of 5.2% and a 47.07% success rate. Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Neurocrine, and Travere Therapeutics.
In another report released on January 29, TD Cowen also assigned a Buy rating to the stock with a $24.00 price target.